Deal Worth Up to $300M
Sideris: $32M Series A Round, Novartis Could Buy Company
By Randy Osborne
Wednesday, October 23, 2013
Not yet fully emerged from stealth mode, Sideris Pharmaceuticals Inc. made known its $32 million Series A round as well as a potential $300 million deal with Novartis AG that includes the right to acquire Sideris and the iron-chelating candidate SP-420.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.